Role of additives like polymers and surfactants in the crystallization of mebendazole

Yakugaku Zasshi

Volumn 128, Issue 2, 2008, Pages 281-289

  Kumar, Smiti ^a   Chawla, Garima ^a   Bansal, Arvind K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Crystal habit; Crystallization; Dissolution; Mebendazole; Polymer; Surfactant

Indexed keywords

DODECYL SULFATE SODIUM; DRUG ADDITIVE; MEBENDAZOLE; POLYMER; POVIDONE; SURFACTANT;

ANALYTIC METHOD; ARTICLE; CRYSTALLIZATION; DRUG RELEASE; DRUG SOLUBILITY; NEEDLE;

CRYSTALLIZATION; MEBENDAZOLE; POLYMERS; POVIDONE; SODIUM DODECYL SULFATE; SOLUTIONS; SURFACE-ACTIVE AGENTS; WATER;

EID: 39049138329     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.128.281     Document Type: Article

References (29)

1. Guillory J. K., "Polymorphism in Pharmaceutical Solids," Marcel Dekker, New York, 1999, pp. 183-226.
2. Brittan H. G., Vippagunta S. R., Grant D. J. W., Adv. Drug Delev. Rev., 48, 3-26 (2001).
3. Hornedo N. R., "Encyclopedia of Pharmaceutical Technology," Marcel Dekker, New York, 1990, pp. 399-434.
4. Hornedo N. R., J. Pharm. Sci., 88, 651-660 (1999).
5. Rusconi F., Valton E., Nguyen R., Dufourc E., Anal. Biochem., 295, 31-37 (2001).
6. ICH "International Conference on Harmonisation on Technical Requirements for Registration of pharmaceuticals for Human Use. Guideline on Validation of Analytical Procedure: Methodology. Q2B. Step 4 draft." International Conference on Harmonisation, Geneva 1997.
7. Dilawar, M. M. N., "Reverse Engineering of Pharmaceutical Formulations," Department of Pharmaceutical Technology (Formulations), M. Pharm, NIPER, Mohali, Punjab, 2005, pp. 30, 46.
8. Swanepoel E., Liebenberg W., Devarakonda B., DE. Villiers M. M., Pharmazie, 58, 117-121 (2003).
9. Lee T., Kuo C. S., Chen Y. H., Pharm. Tech., 30, 72-90 (2006).
10. Lu G. W., Smith M., Geiger B. M., Pfund W., J. Pharm. Sci., 95, 305-317 (2006).
11. Raghavan L., Davis A. F., Hadgraft J., Int. J. Pharm., 212, 213-221 (2001).
12. Chawla G., Gupta P., Thilagavathi R., Chakraborti A. K., Bansal A. K., Eur. J. Pharm. Sci., 20, 305-317 (2003).
13. Tiwary A. K., Drug Dev. Ind. Pharm., 27, 699-709 (2001).
14. Chao R. S., Vail K. C., Pharm. Res., 4, 429-432 (1987).
15. Bandyopadhyay R., Selbo J., Amidon G. E., Hawley M., J. Pharm Sci., 94, 2520-2530 (2005).
16. US Food and Drug Administration, Guidance for Industry, Dissolution Testing of Immediate Release Solid Oral Dosage Forms, Rockville, MD, USA, 1997.
17. Hara T. O., Dunne A., Butler J., Devane J., J. Pharm. Sci. Tech. Today, 1, 214-223 (1998).
18. Sekikawa H., Arita T., Chem. Pharm. Bull., 26, 118-126 (1978).
19. Corrigan O. I., Drug Dev. Ind. Pharm., 11, 697-724 (1985).
20. Craig D. Q. M., Int. J. Pharm., 231, 131-144 (2002).
21. Abd E. B. A., Foda N., Tayel S., Badawi S. S., Drug Dev. Ind. Pharm., 16, 1649-1660 (1990).
22. Usui F., Kusai A., Nishimura K., Yamamoto K., Int. J. Pharm., 154, 59-66 (1997).
23. Naima Z., Siro T., Juan-Manuel G. D., Chantal C., René C., Jerome D., Eur. J. Pharm. Sci., 12, 395-404 (2001).
24. Oharriz M., Goni M. M., Espinosa C. R., Ilarduya M. C. T., Zornoza A., Eur. J. Pharm. Sci., 8, 127-132 (1999).
25. Rasenack N., Int. J. Pharm., 245, 9-24 (2002).
26. Lee T., Kuo C. S., Chen Y. H., Pharm. Tech., 30, 72-90 (2006).
27. Chiou W. L., Athanikar N., J. Pharm. Sci., 65, 1702-1704 (1976).
28. Mackellar A. J., Newton J. M., Chowdhary B. Z., Orr C. A., Int. J. Pharm., 112, 65-78 (1994).
29. Nikander A. B., Christiansen L., Yliruusi J., AAPS Pharm. Sci. Tech., 4, E44 (2003).